FLT3 Mutation Analysis
Use
The FLT3 Mutation Analysis assay qualitatively detects FLT3 ITD and TKD mutations and is intended primarily for use with patients newly diagnosed with AML to assist with therapeutic, diagnostic, and prognostic treatment decisions.
Special Instructions
Frozen blood and bone marrow samples are NOT accepted. Extracted DNA: Isolation of nucleic acids for clinical testing must occur in a CLIA-certified laboratory or a laboratory meeting equivalent requirements. Concentration and volume must be provided for all samples.
Limitations
The assay is specifically designed to detect FLT3 ITD and TKD mutations. It may not identify other mutations outside of these targeted regions. Additionally, the test is intended for clinical use and subject to protocol requirements specified in biopharma study contracts.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5mL
Minimum Volume
3mL
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 8°C
Causes for Rejection
Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimens beyond stability; Insufficient DNA isolated
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 30 days |
| Frozen | Long Term |